Solinasin Tablet 10 mg (Solifenacin Succinate)

Adult dose

The usual recommended dose for adults (including older adults) is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This medicine may be taken with or without food and should be swallowed whole with water. The dosage regimen must be adjusted for the following patients. 1. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use with caution in patients with severe renal impairment (creatinine clearance≤30ml/min), and do not exceed 5mg once daily. 2. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. Use with caution in patients with moderate hepatic impairment (Child-Pugh class B), and do not exceed 5mg once daily. 3. Patients taking a strong cytochrome P450 3A4(CYP3A4) inhibitor For patients taking ketoconazole or another strong CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This medication should not be administered to patients with urinary retention, severe gastrointestinal disorders, myasthenia gravis, or angle-closure glaucoma. Additionally, it should be avoided in individuals who have a hypersensitivity to this medication or its components, patients undergoing hemodialysis, patients with severe liver impairment, severe renal impairment, and those taking strong CYP3A4 inhibitors. Patients at risk for urinary retention or with gastrointestinal obstruction, reduced gastrointestinal motility, severe renal impairment, or moderate liver impairment should be given this medication with caution. This medication may commonly cause side effects such as dry mouth, constipation, blurred vision, urinary retention, dry eyes, etc., with an increased incidence of side effects particularly at higher doses. Severe allergic reactions such as angioedema or anaphylaxis may occur, so if symptoms arise, administration should be immediately stopped and medical attention sought. Caution is needed when driving or operating machinery due to the possibility of drowsiness, blurred vision, and fatigue. This medication may enhance the effects or side effects of other anticholinergic drugs when used together and may reduce the effectiveness of prokinetic agents. Moreover, since this medication is metabolized by CYP3A4 enzymes, dose adjustments may be necessary when taken with strong CYP3A4 inhibitors. Women who are pregnant or breastfeeding must consult a specialist before using this medication, and safety in pediatric patients has not been established, so use is generally not recommended. In case of overdose, it is important to visit a medical facility promptly for appropriate treatment, as severe central nervous system symptoms or cardiac irregularities may occur, requiring caution. Although this medication is known not to increase the risk of tumor development with long-term use, careful evaluation of the patient's condition and thorough monitoring is necessary before administration.

• dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• fecal impaction
• colonic obstruction
• intestinal obstruction
• angioedema
• nausea

This medication should be stored in a sealed container to protect it from air and moisture, preferably at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer duration.

Appearance

Bright pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)